The two phases
Key facts
- Pyrazinamide stops at two months: most benefit comes early, and longer use adds to hepatotoxicity.
- Ethambutol is given only until susceptibility results are known.
- Patients feel better within weeks, but persistent organisms remain, and stopping early risks relapse.
The bacilli in one patient are not all alike: some grow fast, some live inside macrophages or in acidic lesions, and some persist long after the patient feels better. Each drug acts on only some of them.
- Day one: Intensive phase, RHZE
- The bacillary load is at its highest. It holds small numbers of organisms naturally resistant to any one drug. Four drugs start together because several drugs suppress those organisms.
- Week two: Intensive phase, RHZE
- The patient can feel better within the first few weeks, but the infection hasn't gone.
- Month two: Intensive phase ends
- Pyrazinamide stops: most of its benefit comes early, and longer use adds to its hepatotoxicity. Ethambutol stops too. Rifampicin and isoniazid go on.
- Month four: Continuation phase, RH
- Isoniazid and rifampicin, the two main drugs, go on alone. They clear organisms that persist after the intensive phase.
- Month six: Course complete
- Treatment for drug-susceptible tuberculosis lasts at least six months.
| Drug | Phase | Reason |
|---|---|---|
| Isoniazid | Both phases | One of the two main drugs; acts on rapidly growing bacilli |
| Rifampicin | Both phases | One of the two main drugs; kills inside and outside cells |
| Pyrazinamide | Intensive phase only | Most benefit comes early; longer use adds to hepatotoxicity |
| Ethambutol | Intensive phase only | Included until susceptibility results are known |